StreetInsider.com News Articles

Form 4 MediWound Ltd. For: Jun 01 Filed by: Fox David Morton

Tue, 02 Jun 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26587484.html

Form 4 MediWound Ltd. For: Jun 01 Filed by: Fox David Morton

Tue, 02 Jun 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26587484.html

Form 4 MediWound Ltd. For: May 29 Filed by: Rubinstein Samuel

Mon, 01 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260601/26578934.html

Form 4 MediWound Ltd. For: May 29 Filed by: Rubinstein Samuel

Mon, 01 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260601/26578934.html

MediWound Ltd (MDWD) PT Lowered to $32 at Oppenheimer

Wed, 27 May 2026 16:07:00 -0400

Oppenheimer analyst Jay Olson lowered the price target on MediWound Ltd (NASDAQ: MDWD) to $32.00 (from $33.00) while maintaining a Outperform rating.

The analyst comments "On Wednesday, MDWD reported 1Q26 results and provided a business update (press release; slides). 1Q26 revenues came in at $1.5M, below our and Street estimates of $3.3M/3.4M, impacted by the delay in both the anticipated BARDA-related revenues and shipments affected by the conflict in the Middle East. Despite the lower than anticipated 1Q26 revenues, management remains confident in their prior guidance for full-year revenue of $24-26M. Management commented that delayed shipments in 1Q26 have now been

MediWound Ltd (MDWD) PT Lowered to $32 at Oppenheimer

Wed, 27 May 2026 16:07:00 -0400

Oppenheimer analyst Jay Olson lowered the price target on MediWound Ltd (NASDAQ: MDWD) to $32.00 (from $33.00) while maintaining a Outperform rating.

MediWound (MDWD) Tops Q1 EPS by 42c

Wed, 27 May 2026 07:37:16 -0400

MediWound (NASDAQ: MDWD) reported Q1 EPS of ($0.23), $0.42 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $1.48 million versus the consensus estimate of $3.28 million.

For earnings history and earnings-related data on MediWound (MDWD) click here.

Form 6-K MediWound Ltd. For: May 27

Wed, 27 May 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260527/26553404.html

Form 6-K MediWound Ltd. For: May 27

Wed, 27 May 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260527/26553404.html

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 27 May 2026 07:00:00 -0400

EscharEx^® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027

First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million

Conference Call Today, May 27, 2026, at 8:30 a.m. Eastern Time

YAVNE, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.

“During the first quarter,

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 27 May 2026 07:00:00 -0400

EscharEx^® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027

First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million

Conference Call Today, May 27, 2026, at 8:30 a.m. Eastern Time

“During the first quarter,

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 27 May 2026 07:00:00 -0400

EscharEx^® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027

First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million

Conference Call Today, May 27, 2026, at 8:30 a.m. Eastern Time

“During the first quarter,

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 27 May 2026 07:00:00 -0400

EscharEx^® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027

First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million

Conference Call Today, May 27, 2026, at 8:30 a.m. Eastern Time

“During the first quarter,

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 27 May 2026 07:00:00 -0400

EscharEx^® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027

First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million

Conference Call Today, May 27, 2026, at 8:30 a.m. Eastern Time

“During the first quarter,

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 27 May 2026 07:00:00 -0400

EscharEx^® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027

First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million

Conference Call Today, May 27, 2026, at 8:30 a.m. Eastern Time

“During the first quarter,

Form SCHEDULE 13G MediWound Ltd. Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 15 May 2026 10:08:00 -0400

si-local-file:///var/storage/secattach/20260515/26501309.html

Form SCHEDULE 13G MediWound Ltd. Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 15 May 2026 10:08:00 -0400

si-local-file:///var/storage/secattach/20260515/26501309.html

MediWound to Report First Quarter 2026 Financial Results

Thu, 07 May 2026 08:00:00 -0400

MediWound to Report First Quarter 2026 Financial Results

Conference Call and Webcast Scheduled for Wednesday, May 27th at 8:30 a.m. Eastern Time

YAVNE, Israel, May 7, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the first quarter ended March 31, 2026 on Wednesday, May 27, 2026.

Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

MediWound to Report First Quarter 2026 Financial Results

Thu, 07 May 2026 08:00:00 -0400

MediWound to Report First Quarter 2026 Financial Results

Conference Call and Webcast Scheduled for Wednesday, May 27th at 8:30 a.m. Eastern Time

Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

MediWound to Report First Quarter 2026 Financial Results

Thu, 07 May 2026 08:00:00 -0400

MediWound to Report First Quarter 2026 Financial Results

Conference Call and Webcast Scheduled for Wednesday, May 27th at 8:30 a.m. Eastern Time

Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

MediWound to Report First Quarter 2026 Financial Results

Thu, 07 May 2026 08:00:00 -0400

MediWound to Report First Quarter 2026 Financial Results

Conference Call and Webcast Scheduled for Wednesday, May 27th at 8:30 a.m. Eastern Time

Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Form 6-K MediWound Ltd. For: May 06

Wed, 06 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260506/26443594.html

Form 6-K MediWound Ltd. For: May 06

Wed, 06 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260506/26443594.html

MediWound highlights consensus supporting wound treatment strategy

Mon, 13 Apr 2026 07:31:20 -0400

MediWound Ltd. (NASDAQ: MDWD) announced that a peer-reviewed consensus published in WOUNDS journal aligns with the company's approach to chronic wound treatment. The consensus, authored by U.S. wound care experts, presents a framework for debridement approaches across different care settings.

The panel redefined debridement beyond simple tissue removal to include biologically active interventions that reduce biofilm and bacterial burden while reactivating wound healing processes. The experts emphasized using effective, less invasive treatments initially before considering more aggressive surgical methods.

The consensus noted that no single current treatment addresses all clinical needs, highlighting the importance of flexible treatment strategies. MediWound stated this supports

Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement

Mon, 13 Apr 2026 07:30:00 -0400

Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement

Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive biologically active driver of wound healing

Panel supports early use of effective, less invasive treatments in chronic wound care, reinforcing the commercial thesis for EscharEx® in chronic wound care

YAVNE, Israel, April 13, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today highlighted the publication of a peer-reviewed supplement in WOUNDS titled “Toward a Practical Framework